Reversible Conformational Change in the Plasmodium falciparum Circumsporozoite Protein Masks Its Adhesion Domains.

PubWeight™: 0.83‹?›

🔗 View Article (PMID 26169272)

Published in Infect Immun on July 13, 2015

Authors

Raul Herrera1, Charles Anderson1, Krishan Kumar1, Alvaro Molina-Cruz2, Vu Nguyen1, Martin Burkhardt1, Karine Reiter1, Richard Shimp1, Randall F Howard3, Prakash Srinivasan2, Michael J Nold4, Daniel Ragheb5, Lirong Shi5, Mark DeCotiis1, Joan Aebig1, Lynn Lambert1, Kelly M Rausch1, Olga Muratova1, Albert Jin6, Steven G Reed3, Photini Sinnis5, Carolina Barillas-Mury2, Patrick E Duffy1, Nicholas J MacDonald1, David L Narum7

Author Affiliations

1: Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
2: Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
3: Infectious Disease Research Institute, Seattle, Washington, USA.
4: Waters Corp., Milford, Massachusetts, USA.
5: Johns Hopkins Malaria Research Institute and Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
6: Laboratory of Cellular Imaging and Macromolecular Biophysics, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland, USA.
7: Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA dnarum@niaid.nih.gov.

Articles cited by this

A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature (2013) 11.03

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med (2011) 10.79

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med (1997) 8.22

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med (2012) 6.64

Absolute quantification of proteins by LCMSE: a virtue of parallel MS acquisition. Mol Cell Proteomics (2005) 6.37

Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science (2013) 5.53

Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. Mol Biochem Parasitol (1994) 3.36

Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J Exp Med (1982) 3.26

Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine (2007) 2.88

Heparan sulfate proteoglycans provide a signal to Plasmodium sporozoites to stop migrating and productively invade host cells. Cell Host Microbe (2007) 2.64

Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol (2008) 2.63

Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc Natl Acad Sci U S A (2013) 2.10

A malaria merozoite surface protein (MSP1)-structure, processing and function. Mem Inst Oswaldo Cruz (1992) 1.91

Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite. Cell (2007) 1.90

The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion. J Exp Med (2005) 1.85

The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host. J Exp Med (2011) 1.62

Simple centrifugation method for rapid separation of sporozoites from mosquitoes. J Parasitol (1984) 1.62

The binding of the circumsporozoite protein to cell surface heparan sulfate proteoglycans is required for plasmodium sporozoite attachment to target cells. J Biol Chem (2001) 1.52

Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein. J Immunol (2002) 1.41

Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate. J Biol Chem (2009) 1.41

Structural similarities among the protective antigens of sporozoites from different species of malaria parasites. J Biol Chem (1983) 1.29

Shedding of TRAP by a rhomboid protease from the malaria sporozoite surface is essential for gliding motility and sporozoite infectivity. PLoS Pathog (2012) 1.16

Unexpected fold in the circumsporozoite protein target of malaria vaccines. Proc Natl Acad Sci U S A (2012) 1.14

Antimalarial activity of allicin, a biologically active compound from garlic cloves. Antimicrob Agents Chemother (2006) 1.14

An immunologically cryptic epitope of Plasmodium falciparum circumsporozoite protein facilitates liver cell recognition and induces protective antibodies that block liver cell invasion. J Biol Chem (2005) 1.14

Immunization with a functional protein complex required for erythrocyte invasion protects against lethal malaria. Proc Natl Acad Sci U S A (2014) 1.12

The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity. Vaccine (2008) 1.11

The Plasmodium circumsporozoite protein is involved in mosquito salivary gland invasion by sporozoites. Mol Biochem Parasitol (2004) 1.10

Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle. Vaccine (2013) 1.07

A rapid and scalable density gradient purification method for Plasmodium sporozoites. Malar J (2012) 1.01

Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I·C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mice. Infect Immun (2012) 1.01

Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion. Infect Immun (2011) 0.97

Molecular mechanism of host specificity in Plasmodium falciparum infection: role of circumsporozoite protein. J Biol Chem (2003) 0.93

Analysis of the processing of Plasmodium falciparum rhoptry-associated protein 1 and localization of Pr86 to schizont rhoptries and p67 to free merozoites. Mol Biochem Parasitol (1998) 0.92

Plasmodium vivax: a monoclonal antibody recognizes a circumsporozoite protein precursor on the sporozoite surface. Exp Parasitol (1998) 0.89

Proteolytic Cleavage of the Plasmodium falciparum Circumsporozoite Protein Is a Target of Protective Antibodies. J Infect Dis (2015) 0.84

Formation of the circumsporozoite protein of Plasmodium falciparum in Anopheles stephensi. Acta Trop (1988) 0.82

Chelation of Ca²⁺ ions by a peptide from the repeat region of the Plasmodium falciparum circumsporozoite protein. Malar J (2014) 0.77